Krystal Biotech’s (KRYS) “Buy” Rating Reaffirmed at HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $361.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 9.31% from the company’s previous close.

KRYS has been the topic of a number of other research reports. Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, October 9th. Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. William Blair raised Krystal Biotech to a “strong-buy” rating in a research note on Wednesday, September 23rd. Jefferies Financial Group reissued a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a research note on Monday, July 13th. Finally, Bank of America raised their price target on Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $377.20.

Krystal Biotech Price Performance

Shares of KRYS stock traded down $0.45 during trading hours on Thursday, hitting $330.24. 181,782 shares of the company’s stock were exchanged, compared to its average volume of 327,874. The stock’s 50-day moving average is $340.46 and its 200-day moving average is $322.60. The stock has a market cap of $9.77 billion, a price-to-earnings ratio of 41.38 and a beta of 0.50. Krystal Biotech has a 52 week low of $183.03 and a 52 week high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. The company had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Equities research analysts forecast that Krystal Biotech will post 7.47 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the sale, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the sale, the director directly owned 50,000 shares in the company, valued at approximately $16,456,000. This represents a 33.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds have recently modified their holdings of the business. Terra Nova Asset Management LLC bought a new position in Krystal Biotech in the third quarter valued at approximately $828,000. GK Wealth Management LLC bought a new position in Krystal Biotech in the third quarter valued at approximately $59,000. GAMMA Investing LLC grew its stake in Krystal Biotech by 10.2% in the third quarter. GAMMA Investing LLC now owns 1,100 shares of the company’s stock valued at $366,000 after purchasing an additional 102 shares in the last quarter. Toth Financial Advisory Corp grew its stake in Krystal Biotech by 9.5% in the third quarter. Toth Financial Advisory Corp now owns 4,941 shares of the company’s stock valued at $1,643,000 after purchasing an additional 430 shares in the last quarter. Finally, Congress Asset Management Co. grew its stake in Krystal Biotech by 34.8% in the third quarter. Congress Asset Management Co. now owns 54,083 shares of the company’s stock valued at $17,986,000 after purchasing an additional 13,949 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations.

Krystal Biotech’s lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.